Tag - ALPN

Markets

HCW starts Alpine Immune Sciences at buy; PT $21

H.C. Wainwright launched coverage of Alpine Immune Sciences (NASDAQ:ALPN) with a “buy” rating and $21 price target. The stock finished at $14.57 on Dec. 18. Alpine is leading the way in developing protein-based...

December 21, 2020

Developments

Alpine Immune Sciences gets two FDA orphan drug designations for ALPN-101

Alpine Immune Sciences (NASDAQ:ALPN) received two FDA orphan drug designations for ALPN-101 for the prevention and treatment of acute graft-versus-host disease (GvHD). ALPN-101 is a selective dual T-cell co-stimulation...

March 19, 2020

Tag - ALPN

HCW starts Alpine Immune Sciences at buy; PT $21

Alpine Immune Sciences gets two FDA orphan drug designations for ALPN-101

General

More